-front payment (up-front fee + milestones), regarding drug candidates for specific drug classes, like anticancer or cardiovascular … investigated. Findings: For the anticancer (antineoplastics) and cardiovascular drug classes, the formula to predict the royalty … the relationship between two drug classes-anticancer (antineoplastics) and cardiovascular-and royalty-related data …

), regarding drug candidates for specific drug class of anticancer by regression analysis. Then, the formula to predict royalty … anticancer (antineoplastics) drug classes, the formula to predict the royalty rate and up-front payment is as follows. <Drug … relationship between multiple input variables and royalty-related data in one drug class of anticancer (antineoplastics). Practical …

2009;milestones), regarding drug candidates for specific drug class of anticancer by regression analysis. Then, the formula …-related data in one drug class of anticancer (antineoplastics). Practical implications (if applicable) Valuation for the drug …). Findings: For the anticancer (antineoplastics) drug classes, the formula to predict the royalty rate and up-front payment is as …

) measures, we explored to what extent collaborative licensing mechanisms (private ordering measures), such as patent pools and … present paper aims at re-visiting our former insights in a present-day context. First, we re-examine the patent proliferation … phenomenon and related anti-commons problem by investigating the patent growth and re-assessing the existence of patent thickets …